Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.
| 4.8 | |
| 5 | |
| - | |
| 5 | |
| 4.8 | |
| 4.7-40.4 | |
| 227 M | |
| 172 M | |
| 1 000 K | |
| 0 | |
| 2.0447 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Results in PDX model of pancreatic cancer supports planned IND for NT219 Completes acquisition of substantially all minority shares of TyrNovo, June 15, 2018 TEL AVIV, Israel, June 15, 2018 (GLOBE...
TEL AVIV, Israel, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) (TASE:KTOV), an innovative biopharmaceutical company, announced today that, following its acquis...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
